Should I buy or sell PDS Biotechnology stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PDSB shares. View PDSB analyst ratings or view top-rated stocks .

What is PDS Biotechnology's stock price target for 2024?

4 equities research analysts have issued 12-month price targets for PDS Biotechnology's stock. Their PDSB share price targets range from $11.00 to $21.00. On average, they expect the company's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 497.7% from the stock's current price. View analysts price targets for PDSB or view top-rated stocks among Wall Street analysts .

How have PDSB shares performed in 2024?

PDS Biotechnology's stock was trading at $4.97 on January 1st, 2024. Since then, PDSB shares have decreased by 41.6% and is now trading at $2.90. View the best growth stocks for 2024 here .

When is PDS Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PDSB earnings forecast .

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. During the same period in the previous year, the firm earned ($0.23) earnings per share.

What other stocks do shareholders of PDS Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDS Biotechnology investors own include Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , Advanced Micro Devices (AMD) , Boxlight (BOXL) , Otonomy (OTIC) , Bionano Genomics (BNGO) , CymaBay Therapeutics (CBAY) , Cerecor (CERC) , Enterprise Products Partners (EPD) and Evofem Biosciences (EVFM) .

Who are PDS Biotechnology's major shareholders?

PDS Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include Inspirion Wealth Advisors LLC (0.97%) and Kathleen S. Wright Associates Inc. (0.02%). Insiders that own company stock include Delyle W Bloomquist, Matthew C Hill , Steve C Glover and Voorhees Seth Van . View institutional ownership trends .

How do I buy shares of PDS Biotechnology?

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PDSB

PDS Biotechnology (PDSB) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free PDSB Stock Alerts

$2.90

+0.18 (+6.62%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.69
▼
$3.02
50-Day Range: $2.72
▼
$6.59
52-Week Range: $2.68
▼
$10.27

Volume: 1.13 million shs
Average Volume: 884,359 shs
Market Capitalization: $106.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.33

Get PDS Biotechnology alerts:

PDS Biotechnology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 497.7% Upside
$17.33 Price Target
Short Interest: Bearish
16.77% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.55) to ($1.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.86 out of 5 stars

Medical Sector

825th out of 918 stocks

Pharmaceutical Preparations Industry

364th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
PDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
PDS Biotechnology has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
16.77% of the outstanding shares of PDS Biotechnology have been sold short.
Short Interest Ratio / Days to Cover
PDS Biotechnology has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in PDS Biotechnology has recently increased by 11.62%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
PDS Biotechnology does not currently pay a dividend.
Dividend Growth
PDS Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PDSB.

2.9

News and Social Media Coverage

News Sentiment
PDS Biotechnology has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
Search Interest
Only 14 people have searched for PDSB on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
4 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 10.00% of the stock of PDS Biotechnology is held by insiders.
Percentage Held by Institutions
Only 26.84% of the stock of PDS Biotechnology is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.55) to ($1.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PDS Biotechnology is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PDS Biotechnology is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PDS Biotechnology has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About PDS Biotechnology Stock (NASDAQ:PDSB)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

PDSB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PDSB Stock News Headlines

April 5, 2024 | investing.com

PDS Biotechnology Corp (PDSB)

April 3, 2024 | msn.com

Luminous quasar PDS 456 explored with MUSE

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 30, 2024 | finance.yahoo.com

PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions

March 29, 2024 | ca.style.yahoo.com

Twitch online gamer Ninja says he has form of skin cancer in 'early stages'

March 28, 2024 | finance.yahoo.com

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript

March 28, 2024 | finance.yahoo.com

Q4 2023 PDS Biotechnology Corp Earnings Call

March 27, 2024 | finance.yahoo.com

PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 27, 2024 | investorplace.com

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023

March 27, 2024 | globenewswire.com

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

March 27, 2024 | msn.com

PDS Biotechnology FY 2023 Earnings Preview

March 20, 2024 | globenewswire.com

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

March 18, 2024 | msn.com

MP: Authorities Grappling With Suspicious PDS Wheat Black Marketing

March 17, 2024 | msn.com

MP: Police Seize 30 Sacks Of PDS Rice Out For Black Marketing

March 14, 2024 | msn.com

GFA, PDS Ventures to invest $200,000 in new fashion innovators

March 13, 2024 | investorplace.com

The 3 Most Undervalued Biotech Stocks to Buy in March 2024

March 13, 2024 | globenewswire.com

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

January 26, 2024 | seekingalpha.com

PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data

January 23, 2024 | msn.com

PDS Biotech names Kirk V. Shepard as Chief Medical Officer

January 16, 2024 | finance.yahoo.com

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

January 16, 2024 | finance.yahoo.com

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

January 2, 2024 | finance.yahoo.com

All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy

December 17, 2023 | ca.finance.yahoo.com

PDSB Jan 2024 7.500 call

December 16, 2023 | ca.finance.yahoo.com

PDSB Jan 2024 7.500 put

December 16, 2023 | ca.finance.yahoo.com

PDSB Feb 2024 7.500 call

December 8, 2023 | benzinga.com

PDS Biotechnology Stock (NASDAQ:PDSB) Dividends: History, Yield and Dates

See More Headlines

Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PDSB
CUSIP: N/A
CIK: 1472091
Web: www.pdsbiotech.com
Phone: (800) 208-3343
Fax: 908-790-1212
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.33
High Stock Price Target: $21.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +483.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,940,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -138.44%
Return on Assets: -69.04%

Debt

Debt-to-Equity Ratio: 0.75
Current Ratio: 4.33
Quick Ratio: 4.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.84 per share
Price / Book: 3.54

Miscellaneous

Outstanding Shares: 36,680,000
Free Float: 33,011,000
Market Cap: $108.94 million
Optionable: Optionable
Beta: 1.67

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Frank K. Bedu-Addo Ph.D. (Age 59)
President, CEO & Director
Comp: $854.1k
Mr. Lars Robert Boesgaard M.B.A. (Age 54)
Chief Financial Officer
Dr. Joe J. Dervan
VP of Research & Development
Dr. Gregory L. Conn Ph.D. (Age 69)
Chief Scientific Officer
Comp: $220.46k
Ms. Deanne Randolph
Head of Investor Relations
Mr. Spencer Brown J.D. (Age 54)
Senior VP & General Counsel
Dr. Kirk V. Shepard M.D.
Chief Medical Officer
Ms. Janetta Trochimiuk (Age 61)
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PDSB Stock Analysis - Frequently Asked Questions

Should I buy or sell PDS Biotechnology stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PDSB shares.
View PDSB analyst ratings or view top-rated stocks.
What is PDS Biotechnology's stock price target for 2024?: 4 equities research analysts have issued 12-month price targets for PDS Biotechnology's stock. Their PDSB share price targets range from $11.00 to $21.00. On average, they expect the company's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 497.7% from the stock's current price.
View analysts price targets for PDSB or view top-rated stocks among Wall Street analysts.
How have PDSB shares performed in 2024?: PDS Biotechnology's stock was trading at $4.97 on January 1st, 2024. Since then, PDSB shares have decreased by 41.6% and is now trading at $2.90.
View the best growth stocks for 2024 here.
When is PDS Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PDSB earnings forecast.

How were PDS Biotechnology's earnings last quarter?: PDS Biotechnology Co. (NASDAQ:PDSB) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. During the same period in the previous year, the firm earned ($0.23) earnings per share.
What other stocks do shareholders of PDS Biotechnology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PDS Biotechnology investors own include Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Boxlight (BOXL), Otonomy (OTIC), Bionano Genomics (BNGO), CymaBay Therapeutics (CBAY), Cerecor (CERC), Enterprise Products Partners (EPD) and Evofem Biosciences (EVFM).
Who are PDS Biotechnology's major shareholders?: PDS Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include Inspirion Wealth Advisors LLC (0.97%) and Kathleen S. Wright Associates Inc. (0.02%). Insiders that own company stock include Delyle W Bloomquist, Matthew C Hill, Steve C Glover and Voorhees Seth Van.
View institutional ownership trends.
How do I buy shares of PDS Biotechnology?: Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PDSB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PDS Biotechnology (PDSB) Stock Price, News & Analysis

PDS Biotechnology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About PDS Biotechnology Stock (NASDAQ:PDSB)

PDSB Stock Price History

PDSB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PDSB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™